Cerebrospinal fluid aβ42 is reduced in multiple system atrophy but normal in Parkinson's disease and progressive supranuclear palsy
Cerebrospinal fluid aβ42 is reduced in multiple system atrophy but normal in Parkinson's disease and progressive supranuclear palsy
复制标题
DOI：
10.1002/mds.10321
复制
发表时间：
2003-02-01
影响因子：
8.6
通讯作者：
Rosengren, L
中科院分区：
文献类型：
--
作者：
Holmberg, B;Johnels, B;Rosengren, L
脑脊液（CSF）中p -淀粉样蛋白Abeta42的42个氨基酸异构体最近被提出作为阿尔茨海默病（AD）和皮层下白质痴呆（SWD）的生化标志物。在这两种条件下，CSF-Abeta42的浓度都降低了。我们量化了符合严格临床标准的多系统萎缩（MSA, n = 36）、帕金森病（PD, n = 48）和进行性核上性麻痹（PSP, n = 15）患者的CSF-Abeta42。研究小组被连续招募到一个运动障碍单元的患者中，32名年龄匹配的健康志愿者作为对照。MSA组脑脊液中Abeta42浓度显著降低（P < 0.001），而PD和PSP组与对照组无差异。在个体基础上，无论年龄和病程如何，9例MSA患者均出现低含量的a42。3例病程较长的PD患者血药浓度也较低，而所有PSP患者血药浓度均正常。我们认为CSF-Abeta42浓度的降低可能是MSA发病机制的一个线索。CSF-Abeta42的产量下降，或者更有可能的是，CSF-Abeta42的消耗量增加。该蛋白的分析也可能成为运动障碍单位帕金森综合征临床鉴别的补充。(C) 2002运动障碍学会。
The 42-amino-acid isoform of P-amyloid Abeta42 in the cerebrospinal fluid (CSF) has recently been proposed as a biochemical marker for Alzheimer's disease (AD) and subcortical white-matter dementia (SWD). In both of these conditions, concentration of CSF-Abeta42 is reduced. We quantified CSF-Abeta42 from patients fulfilling strict clinical criteria for multiple system atrophy (MSA; n = 36), Parkinson's disease (PD; n = 48) and progressive supranuclear palsy (PSP; n = 15). The study groups were consecutively recruited among patients referred to a movement disorder unit, and 32 healthy, age-matched volunteers were used as controls. The CSF concentration of Abeta42 was significantly reduced in the MSA group (P < 0.001), whereas the PD and PSP groups did not differ from controls. On an individual basis, low content of A 42 was seen in 9 MSA patients regardless of age and disease duration. Three PD patients with long disease duration also had low concentrations but all PSP patients were normal. We conclude that the reduced CSF-Abeta42 concentration may be a clue to the pathogenesis of MSA. There is a decreased production, or more possible, an increased consumption of CSF-Abeta42. The analysis of this protein may also become a supplement to the clinical differentiation of parkinsonian syndromes in a movement disorder unit. (C) 2002 Movement Disorder Society.